Recent News

By Category: Research

Researchers strike gold with nanotech vaccine

(ScienceDaily) Scientists in the US have developed a novel vaccination method that uses tiny gold particles to mimic a virus and carry specific proteins to the body’s specialist immune cells. The technique differs from the traditional approach of using dead or inactive viruses as a vaccine and was demonstrated in the lab using a specific Read More »

June 26, 2013
| Filed under North America, Countermeasures, and Research
Share

How cholera-causing bacteria respond to pressure

(EurekAlert) Cholera remains common in non-industrialized parts of the world today. It persists in part because V. cholera, the bacteria that causes the disease, is able to survive in diverse environments ranging from the intestinal lumen, to fresh water, to estuaries, to the sea. A study in The Journal of General Physiology provides new insights Read More »

June 25, 2013
| Filed under Africa, Asia/Pacific, Middle East, North America, International, and Research
Share

Researchers Identify Chemical Compounds that Halt Virus Replication

(GlobalBiodefense) Boston University School of Medicine (BUSM) researchers have identified a new chemical class of compounds that have the potential to block genetically diverse viruses from replicating. The findings, published this spring in Chemistry & Biology, could allow for the development of broad-spectrum antiviral medications to treat a number of viruses, including the highly pathogenic Read More »

June 25, 2013
| Filed under North America, Biotechnology, and Research
Share

Basilea awarded contract by BARDA of up to USD 89 million for the development of its novel antibiotic BAL30072

(MarketWired) BAL30072 current multiple ascending dose study reached maximum tolerated dose Further development, including combination studies with carbapenems, planned under BARDA agreement Basel, Switzerland, June 25, 2013 – Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the Biomedical Advanced Research and Development Authority (BARDA), a division within the U.S. Department of Health and Human Services, Read More »

June 25, 2013
| Filed under Europe, North America, Countermeasures, International, and Research
Share

Inhalation anthrax treatment, raxibacumab, gets FDA approval

(TheGlobalDispatch) The U.S. Food and Drug Administration today approved GlaxoSmithKline’s raxibacumab injection to treat inhalation anthrax, a lethal form of the infectious disease caused by breathing in the spores of the bacterium Bacillus anthracis, according to an FDA press release Friday. The approval comes just a month after the Anti-Infective Drugs Advisory Committee for FDA Read More »